Metformin 1a Pharma (Metformin Hydrochloride)

Metformin 1a Pharma belongs to the biguanide class and is indicated for disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Polycystic ovary syndrome: improves insulin resistance and may help restore ovulatory cycles.

• Metformin reduces hepatic gluconeogenesis and increases peripheral glucose uptake by enhancing insulin sensitivity in muscle and adipose tissue. It activates AMP‑activated protein kinase (AMPK), which modulates key enzymes involved in carbohydrate and lipid metabolism, leading to decreased glucose production and improved glycaemic control.

Metformin may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious metabolic disturbances.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: frequent loose stools.
• Abdominal discomfort: cramping or pain.
• Metallic taste: transient alteration of taste.
• Loss of appetite: reduced desire to eat.
• Flatulence: increased intestinal gas.

Serious or Rare Side Effects

• Lactic acidosis: severe metabolic acidosis requiring emergency care.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Vitamin B12 deficiency: may develop with long‑term use.
• Pancreatitis: inflammation of the pancreas.
• Hypoglycaemia (when combined with other glucose‑lowering agents).

Before initiating Metformin 1a Pharma, clinicians should evaluate patient‑specific risk factors and monitor relevant clinical parameters.

• Renal function: assess creatinine clearance and avoid use in severe renal impairment.
• Hepatic function: evaluate liver enzymes to reduce risk of lactic acidosis.
• Cardiovascular status: caution in patients with unstable heart failure.
• Age: start at lower doses in elderly patients and titrate slowly.
• Concomitant alcohol: advise limited intake to minimise lactic acidosis risk.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin 1a Pharma can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis.
• Cimetidine: can increase plasma metformin concentrations.
• Alcohol: potentiates risk of lactic acidosis.
• Carbamazepine: may reduce metformin effectiveness.
• Nitrates: can enhance hypotensive effects.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• ACE inhibitors or ARBs: monitor renal function and potassium.
• Diuretics: assess for dehydration and renal changes.
• Warfarin: occasional alterations in INR values.
• Digoxin: watch for changes in serum levels.